PENNYBUSTER'S PENNY BUSTIN PLAYS!!

[Pennybuster]

Shares of MEI Pharma NASDAQ: $MEIP have been assigned a consensus recommendation of “Hold” from the seven research firms that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $2.25.

In other news, major shareholder Vivo Ventures Vii, Llc sold 390,572 shares of MEI Pharma stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $1.84, for a total value of $718,652.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

MEIP has been the topic of several research reports. Wedbush restated a “hold” rating on shares of MEI Pharma in a research report on Friday, September 4th. Cowen and Company reiterated a “buy” rating on shares of MEI Pharma in a research report on Wednesday, October 7th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of MEI Pharma in a report on Wednesday, September 2nd.

MEI Pharma (NASDAQ:MEIP) traded down 0.7349% during midday trading on Tuesday, hitting $1.6478. 233,965 shares of the stock traded hands. The company’s market cap is $56.28 million. The firm’s 50-day moving average is $1.73 and its 200-day moving average is $1.78. MEI Pharma has a 52-week low of $1.47 and a 52-week high of $7.14.

MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings results on Wednesday, September 2nd. The company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. Analysts predict that MEI Pharma will post ($0.67) EPS for the current year.

MEI Pharma, Inc. is an oncology business. The Firm is concentrated on the clinical development of drugs and treatments for treatment of cancer. The business ‘s portfolio of clinical drug candidates includes Pracinostat, ME- PWT143 and 344. Pracinostat is an orally available histone deacetylase (NASDAQ:MEIP) inhibitor indicated for the treatment of hematologic disorders that are advanced, like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-established mitochondrial inhibitor targeting a mitochondrial element of the terminal respiratory chain complex. PWT143 is an oral inhibitor -kinase (PI3K) delta, a molecular target that plays an essential role in the proliferation and survival of hematologic cancer cells. Pracinostat continues to be examined in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.




http://midsouthnewz.com/mei-pharma-receives-2-25-average-price-target-from-analysts-nasdaqmeip/20829/